Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks
You may also be interested in...
Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia
Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years
Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia
Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years
Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia
The not-for-profit Asian Cancer Research Group will focus initially on identifying biomarkers for lung and gastric cancers.